Despite the fact that hepatitis C virus (HCV) persists chronically in about 80 percent of those infected, some liver cells remain free of the virus even after many years. Now Sung Key Jang of Pohang University of Science ...
Sep 19, 2011
0
0
The drug combination sofosbuvir/velpatasvir (trade name: Epclusa) has been approved since July 2016 for the treatment of patients with chronic hepatitis C (CHC). In an early benefit assessment, the German Institute for Quality ...
Oct 17, 2016
0
1
University of Washington researchers have made a discovery that sheds light on why the human body is unable to adequately fight off HIV infection.
Jul 12, 2012
0
0
Researchers have discovered the mechanism behind one of the Ebola virus' most dangerous attributes: its ability to disarm the adaptive immune system.
May 2, 2013
0
0
(HealthDay)—Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 infection among people without cirrhosis ...
Jul 25, 2015
0
21
For many patients with the hepatitis C virus (HCV), direct antiviral agents (DAA) offer a potential cure for the disease. The Food and Drug Administration (FDA) has recently approved two new DAAs, telaprevir and boceprevir, ...
May 25, 2011
1
0
(Medical Xpress) -- Researchers in the Department of Virology and the Clinical Department of Thoracic Surgery at the MedUni Vienna have demonstrated that the risk of cytomegalovirus infection following lung transplant can ...
Jun 25, 2012
0
0
(HealthDay)—For patients with hepatitis C virus (HCV) treated with pegylated interferon-alpha and ribavirin (P/R), drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according ...
Oct 11, 2012
0
0
Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.
May 6, 2013
0
0
(HealthDay)—Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes 1 through ...
Oct 1, 2019
0
2
